Edition:
United States

ADMA Biologics Inc (ADMA.OQ)

ADMA.OQ on NASDAQ Stock Exchange Capital Market

2.57USD
2:55pm EST
Change (% chg)

$-0.01 (-0.39%)
Prev Close
$2.58
Open
$2.57
Day's High
$2.58
Day's Low
$2.50
Volume
26,983
Avg. Vol
27,691
52-wk High
$5.74
52-wk Low
$2.02

Latest Key Developments (Source: Significant Developments)

Adma Biologics prices follow-on offering of 17.0 mln shares
Thursday, 9 Nov 2017 08:58am EST 

Nov 9 (Reuters) - Adma Biologics Inc :Adma Biologics announces pricing of follow-on offering.Adma Biologics Inc - ‍pricing of offering of approximately 17.0 million shares of its common stock at price of $2.15 per share​.  Full Article

ADMA Biologics now sees offering‍​ of 13.6 mln shares of common stock - SEC filing
Wednesday, 8 Nov 2017 03:38pm EST 

Nov 8 (Reuters) - ADMA Biologics Inc ::Now sees offering‍​ of 13.6 million shares of its common stock, up from previous filing of 10.2 million shares - SEC filing.  Full Article

ADMA Biologics Q3 loss per share $0.59
Friday, 3 Nov 2017 05:02pm EDT 

Nov 3 (Reuters) - ADMA Biologics Inc ::ADMA Biologics provides corporate update and reports third quarter 2017 financial results.Q3 loss per share $0.59.Q3 earnings per share view $-0.42 -- Thomson Reuters I/B/E/S.Q3 revenue rose 61 percent to $4.7 million.Q3 revenue view $6.5 million -- Thomson Reuters I/B/E/S.  Full Article

ADMA Biologics says ‍loss per share was $0.59 for fiscal quarter ended Sept 30​
Friday, 3 Nov 2017 04:58pm EDT 

Nov 3 (Reuters) - Adma Biologics Inc :ADMA Biologics Inc says ‍for fiscal quarter ended September 30, loss per share was $0.59 - SEC filing​.ADMA Biologics Inc - qtrly total revenues $4.7 million versus $2.9 million ‍​.  Full Article

Adma Biologics Inc files for offering of up to $28.75‍​ million of common stock
Wednesday, 11 Oct 2017 04:47pm EDT 

Oct 11 (Reuters) - Adma Biologics Inc ::Adma Biologics Inc files for offering of up to $28.75‍​ million of common stock .  Full Article

ADMA Biologics ‍enters into credit agreement for up to $40 mln with affiliated entities of Marathon Asset Management​
Wednesday, 11 Oct 2017 07:11am EDT 

Oct 11 (Reuters) - ADMA Biologics Inc ::ADMA Biologics Inc - ‍entered into a credit agreement for up to $40 million with affiliated entities of marathon asset management​.ADMA Biologics - ‍will use proceeds from transaction to refinance principal and accrued interest of outstanding secured loan with oxford finance.  Full Article

ADMA Biologics Q2 loss per share $0.55
Friday, 11 Aug 2017 04:15pm EDT 

Aug 11 (Reuters) - Adma Biologics Inc :ADMA Biologics provides corporate update and reports second quarter 2017 financial results.Q2 loss per share $0.55.Q2 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S.Q2 revenue $3.4 million versus I/B/E/S view $3.3 million.  Full Article

ADMA Biologics provides corporate timeline and activities update
Tuesday, 27 Jun 2017 07:08am EDT 

June 27 (Reuters) - Adma Biologics Inc :ADMA Biologics provides corporate timeline and activities update to stockholders.Anticipate that co will be in a position to refile biologics license application for RI-002 in middle of 2018.Is exploring various financing options which would be expected to allow co to extend current cash runway from Q1 2018 to H2 of 2018.Previously issued warning letter for manufacturing facility cited filter clogging during manufacturing process for Bivigam.Have identified number of possible sources for filter clogging and working to prioritize and resolve these various possibilities.Anticipate manufacturing facility will be ready to begin manufacturing certain products for in approximately 8 weeks."we are focused on relaunching Bivigam".  Full Article

ADMA Biologics Inc files for resale of 6.04 million shares of co's common stock
Friday, 16 Jun 2017 05:14pm EDT 

June 16 (Reuters) - ADMA Biologics Inc ::ADMA Biologics Inc files for resale of 6.04 million shares of co's common stock by the selling shareholders .  Full Article

Biotest ‍sells US therapy business to Adma Biologics, Inc.​
Wednesday, 7 Jun 2017 03:01am EDT 

June 7 (Reuters) - BIOTEST AG ::‍SOLD US THERAPY BUSINESS TO ADMA BIOLOGICS, INC.​.‍RECEIVES 50% MINUS ONE SHARE OF ADMA​.‍RECEIVES ALSO DISTRIBUTION RIGHTS OF SPECIFIED CURRENT PRODUCT AND A RIGHT OF FIRST OFFER FOR DISTRIBUTION OF FUTURE PRODUCTS OF ADMA FOR EUROPE, NEAR AND MIDDLE EAST AND SELECTED ASIAN COUNTRIES​.‍AS PART OF TRANSACTION, BIOTEST HAS CONTRIBUTED EUR11.5 MILLION IN CASH AS WELL AS A EUR14 MILLION LOAN​.  Full Article